Last quarter (Q3 2023), Werewolf Therapeutics's total revenue was $5.90M, an increase of 18.65% from the same quarter last year. In Q3, Werewolf Therapeutics's net income was $-8.29M. See Werewolf Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 6.65M	$ 834.00K	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	$ 750.00K	$ 834.00K	-	-	-
Operating Expense	$ 25.52M	$ 72.46M	$ -50.09M	$ 22.40M	$ 9.94M
Operating Income	$ -60.55M	$ -56.06M	$ -50.09M	$ -22.40M	$ -9.94M
Net Non Operating Interest Income Expense	$ 3.87M	-	$ 104.00K	$ 63.00K	$ -372.00K
Other Income Expense	$ -25.31M	$ -18.65M	-	$ 7.30M	$ 60.00K
Pretax Income	$ -37.26M	$ -53.81M	$ -49.98M	$ -15.04M	$ -10.25M
Tax Provision	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ 4.62M	$ -53.81M	$ -201.93M	$ -28.22M	$ -18.23M
Basic EPS	$ -1.08	$ -1.86	$ -10.94	$ -1.68	$ -2.03
Diluted EPS	$ -1.08	$ -1.86	$ -10.94	$ -1.68	$ -2.03
Basic Average Shares	$ 134.86M	$ 28.86M	$ 18.45M	$ 8.97M	$ 8.97M
Diluted Average Shares	$ 134.86M	$ 28.86M	$ 18.45M	$ 8.97M	$ 8.97M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 25.52M	$ 72.46M	$ -50.09M	$ 22.40M	$ 9.94M
Net Income From Continuing And Discontinued Operation	$ -37.30M	$ -53.81M	$ -49.98M	$ -15.04M	$ -10.25M
Normalized Income	$ -10.57M	$ -42.51M	-	$ -15.04M	$ -9.88M
Interest Expense	-	-	-	-	-
EBIT	$ -40.14M	$ -53.81M	$ -50.09M	$ -22.40M	$ -9.94M
EBITDA	$ -32.49M	$ -51.10M	$ -49.35M	$ -22.25M	$ -9.91M

Currency in USD

Werewolf Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing